UBS109 is an NF-κB inhibitor | CAS#1258513-40-4

MedKoo Cat#: 126698 | Name: UBS109

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UBS109 is an NF-κB inhibitor.

Chemical Structure

UBS109

CAS#1258513-40-4

Theoretical Analysis

MedKoo Cat#: 126698

Name: UBS109

CAS#: 1258513-40-4

Chemical Formula: C18H17N3O

Exact Mass: 291.1372

Molecular Weight: 291.35

Elemental Analysis: C, 74.20; H, 5.88; N, 14.42; O, 5.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

UBS109; UBS 109; UBS-109

IUPAC/Chemical Name

(3E,5E)-1-methyl-3,5-bis(pyridin-2-ylmethylene)piperidin-4-one

InChi Key

VCLPNFMJSSBBKX-WFYKWJGLSA-N

InChi Code

InChI=1S/C18H17N3O/c1-21-12-14(10-16-6-2-4-8-19-16)18(22)15(13-21)11-17-7-3-5-9-20-17/h2-11H,12-13H2,1H3/b14-10+,15-11+

SMILES Code

O=C1/C(CN(C)C/C1=C\C2=NC=CC=C2)=C/C3=NC=CC=C3

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 291.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shoji M, Qian WP, Nagaraju GP, Brat DJ, Pessolano D, Luzietti R, Chennamadhavuni S, Yamaguchi M, Yang L, Liotta DC. Inhibition of breast cancer metastasis to the lungs with UBS109. Oncotarget. 2018 Nov 16;9(90):36102-36109. doi: 10.18632/oncotarget.26302. PMID: 30546830; PMCID: PMC6281413. 2: Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Snyder JP, Mamoru S, El-Rayes BF. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett. 2013 Dec 1;341(2):195-203. doi: 10.1016/j.canlet.2013.08.002. Epub 2013 Aug 7. PMID: 23933177. 3: Rajitha B, Nagaraju GP, Shaib WL, Alese OB, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. Mol Carcinog. 2017 Jan;56(1):288-299. doi: 10.1002/mc.22492. Epub 2016 Apr 29. PMID: 27128654. 4: Yamaguchi M, Zhu S, Zhang S, Wu D, Moore TM, Snyder JP, Shoji M. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis. Cell Tissue Res. 2014 Jul;357(1):245-52. doi: 10.1007/s00441-014-1846-4. Epub 2014 Apr 11. PMID: 24723227. 5: Yamaguchi M, Zhu S, Weitzmann MN, Snyder JP, Shoji M. Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro. Mol Cell Biochem. 2015 Mar;401(1-2):1-10. doi: 10.1007/s11010-014-2286-x. Epub 2014 Nov 22. PMID: 25416449. 6: Yamaguchi M, Moore TW, Sun A, Snyder JP, Shoji M. Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition. Integr Biol (Camb). 2012 Aug;4(8):905-13. doi: 10.1039/c2ib20045g. Epub 2012 Jul 3. PMID: 22751853. 7: Zhu S, Moore TW, Morii N, Howard RB, Culver D, Arrendale RF, Reddy P, Evers TJ, Zhang H, Sica G, Chen ZG, Sun A, Fu H, Khuri FR, Shin DM, Snyder JP, Shoji M. Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. Curr Cancer Drug Targets. 2014;14(4):380-93. doi: 10.2174/1568009614666140312163524. PMID: 24628271. 8: Moore TW, Zhu S, Randolph R, Shoji M, Snyder JP. Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109. ACS Med Chem Lett. 2014 Jan 10;5(4):288-92. doi: 10.1021/ml4002453. PMID: 24900828; PMCID: PMC4027781. 9: Rajitha B, Belalcazar A, Nagaraju GP, Shaib WL, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF. Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. Cancer Lett. 2016 Apr 10;373(2):227-33. doi: 10.1016/j.canlet.2016.01.052. Epub 2016 Feb 2. PMID: 26850372.